Novartis

A global biopharmaceutical company focused on the discovery, development, manufacture and commercialization of prescription medicines. The company operates as an innovative medicines business with established franchises in oncology, cardiovascular and metabolic disease, immunology, neuroscience and selected rare diseases.

Founding and History

Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz. Over time, the company has reshaped its portfolio toward innovative medicines, including the separation of its generics and biosimilars business (Sandoz) into a standalone company in 2023.

Therapy Areas and Focus

Novartis’ core therapeutic priorities include:

Oncology
Cardiovascular, renal and metabolic disease
Immunology and inflammation
Neuroscience
Selected rare diseases

The company’s commercial model is built around global specialty and primary care products, with many programs developed using biomarker-led strategies where applicable.

Technology Platforms and Modalities

Novartis develops medicines across a broad set of modalities, including:

Small molecules
Biologics such as monoclonal antibodies
Radioligand therapies in oncology
Gene and cell therapy approaches (select programs)
RNA-based therapeutics (select programs, including siRNA)

Across modalities, the company emphasizes scalable manufacturing and global supply for products that require specialized production (for example, radioligand and advanced therapy medicines).

Strategic Partnerships and Business Development

Novartis uses partnerships, licensing and acquisitions to complement internal discovery and expand into priority platforms or therapeutic areas. Collaboration models range from early research partnerships through to late-stage co-development and commercialization arrangements, depending on asset maturity and geographic scope.

Key Personnel

Vas Narasimhan, Chief Executive Officer

FAQ Section

Novartis is an innovative medicines company. It invests in R&D to generate differentiated prescription products, then scales them through global development, regulatory execution, manufacturing and commercialization. Revenue is driven primarily by branded medicines, supported by lifecycle management and geographic expansion.

The company prioritizes oncology; cardiovascular, renal and metabolic disease; immunology; neuroscience; and selected rare diseases. These areas reflect long-term portfolio strategy and the company’s current R&D and commercial organization.

Novartis develops both small molecules and biologics, and it has expanded into advanced modalities where there is a clear clinical and operational path to scale. This includes radioligand therapies and selected cell and gene therapy programs, alongside more conventional antibody and small-molecule development.

Radioligand therapy combines a targeting molecule with a radioactive isotope to deliver radiation selectively to cancer cells that express a specific target. For Novartis, it is a strategic oncology modality that can be applied across multiple tumor types where suitable targets exist and where specialized manufacturing and distribution can be executed reliably.

Novartis’ R&D approach emphasizes disease biology, target validation, and clinical trial design aligned to meaningful endpoints in defined patient populations. In many areas, biomarker-driven development is used to improve probability of success and support precision use in clinical practice.

The company combines internal manufacturing networks with external partners, and uses dedicated infrastructure for modalities with distinct production requirements (for example, radioligands and advanced therapies). Execution priorities typically include quality systems, redundancy planning, and regional supply strategies aligned to regulatory and launch needs.

Novartis is positioned as a research-led innovative medicines company with breadth across major therapy areas and increasing modality diversity. Competitive performance is typically determined by pipeline productivity, clinical differentiation, regulatory execution, manufacturing reliability (especially for advanced modalities), and the ability to scale launches globally.

Want to Update your Company's Profile?